EMERGING PARENTERAL DRUG DELIVERY TECHNOLOGIES FOR CONTROLLED AND SUSTAINED THERAPEUTIC DELIVERY.
Main Article Content
Keywords
Parenteral, Ondansetron, Chemotherapy, Palonosetron etc.
Abstract
Chemotherapy induced nausea vomiting is one of the most prevalent side effects caused during the treatment with anticancer drugs. This is overcome by administration of antiemetics particularly 5-hydroxytryptamine (5-HT3) receptor antagonists, like ondansetron hydrochloride and palonosetron hydrochloride. These drugs need to be administered at the start of the chemotherapy on day 1 and then frequently administered till a period of 5 to 6 days intravenously or orally. Conventional oral and parenteral routes suffer from various drawbacks and frequent administration leads to patient incompliance. Controlled release parenteral have been emerging as parenteral drug delivery having various advantages over conventional parenteral such as delivery for a prolonged time period giving uniform drug levels, lowering peak and trough levels and this side effects, reduction in repeated dosing, delivery of drug at a specific site or localized, reduction in overall dose and finally achieving improved patient compliance and comfort.